Results 61 to 70 of about 489,862 (290)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review

Clinical Case Reports, 2017
Key Clinical Message Although tumor lysis syndrome is well described, it is rarely seen or suspected in solid malignancies. Early recognition of this entity is paramount in reducing morbidity and mortality.
David Sommerhalder, Amol M. Takalkar, Rodney Shackelford, Prakash Peddi   +3 more
doaj   +1 more source

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC [PDF]

, 2012
PMCID: PMC3526610This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
A Trojan, AD Hamblin, AG Ramsay, AG Ramsay, AM Krackhardt, AP Kater, AP Kater, BL McClune, C Haller, C Mayr, C Nabhan, CA Rodrigues, D Bagnara, D Dilloo, D Wolf, D Xing, DA Mavroudis, DL Porter, Dongxia Xing, Elizabeth J. Shpall, Hiroshi Shiku, Hong Yang, I Ben-Bassat, I Hus, IF Khouri, J Chen, Jeffrey J. Molldrem, JG Gribben, JG Gribben, JM Rudolph, John G. Gribben, JS Miller, K Kato, M Hoogendorn, M Ritgen, MA King, Matthew M. Halpert, MF Bachmann, Michael J. Keating, N Shah, Nina Shah, R Le Dieu, R Mous, Ruth Lapushin, S Miscia, S Parmar, S Samarasinghe, Simon N. Robinson, Simrit Parmar, SL Martins, SM Schmidt, Sufang Li, T Nishida, WG Wierda, William G. Wierda, William K. Decker, WK Decker   +56 more
core   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Urate Nephropathy from Tumor Lysis Syndrome in an Undiagnosed Case of Prostate Cancer

Current Oncology, 2021
Prostate cancer can masquerade as just normocytic anemia and thrombocytopenia, thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or tumor lysis syndrome (TLS).
Sidra Javed
doaj   +1 more source

KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation. [PDF]

, 2016
KDM2B (also known as FBXL10) controls stem cell self-renewal, somatic cell reprogramming and senescence, and tumorigenesis. KDM2B contains multiple functional domains, including a JmjC domain that catalyzes H3K36 demethylation and a CxxC zinc-finger that
Feng, X, Guan, K-L, Han, X-R, Lei, Q-Y, Xia, Y-K, Xiong, Y, Yuan, H-X, Zha, Z   +7 more
core   +3 more sources

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

the first experience of combined positioning of electrodes in electrochemical destruction of intraocular tumor in experi- ment

Oftalʹmologiâ, 2014
In experiment on fresh enucleated eyes with large tumors it was shown that a new method of electrochemical lysis with original combined positioning of electrodes for intraocular tumors treatment provides a minimal traumatic impact and total destruction ...
Yu. А. Belyy, A. V. Tereshchenko, А. В. Шацких   +2 more
doaj   +3 more sources

Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer

, 2013
Oncolytic virotherapy - the use of viruses that specifically kill tumor cells - is an innovative and highly promising route for treating cancer. However, its therapeutic outcomes are mainly impaired by the host immune response to the viral infection.
Ferreira, Silvio C, Martins, Marcelo L, Paiva, Leticia R, Silva, Hallan S   +3 more
core   +2 more sources